메뉴 건너뛰기




Volumn 5, Issue 5, 2010, Pages 627-649

Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: Overview of efficacy and safety

Author keywords

combination therapy; fenofibric acid; HDL C; LDL C; mixed dyslipidemia; rosuvastatin; triglyceride

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; CERIVASTATIN; CREATINE KINASE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; TRILIPIX; UNCLASSIFIED DRUG;

EID: 78149434089     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.56     Document Type: Review
Times cited : (1)

References (71)
  • 1
    • 0037126526 scopus 로고    scopus 로고
    • Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report
    • Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002).
    • (2002) Circulation , vol.106 , Issue.25 , pp. 3143-3421
  • 2
    • 84865627930 scopus 로고    scopus 로고
    • Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006
    • National Center for Health Statistics, MD, USA
    • Ervin RB: Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. National Health Statistics Reports. National Center for Health Statistics, MD, USA (2009).
    • (2009) National Health Statistics Reports
    • Ervin, R.B.1
  • 3
    • 33747806291 scopus 로고    scopus 로고
    • Metabolic syndrome: The danger signal in atherosclerosis
    • Mathieu P, Pibarot P, Despres JP: Metabolic syndrome: the danger signal in atherosclerosis. Vasc. Health Risk Manag. 2(3), 285-302 (2006).
    • (2006) Vasc. Health Risk Manag. , vol.2 , Issue.3 , pp. 285-302
    • Mathieu, P.1    Pibarot, P.2    Despres, J.P.3
  • 4
    • 34548075248 scopus 로고    scopus 로고
    • Metabolic syndrome: Cardiovascular risk assessment and management
    • Wong ND: Metabolic syndrome: cardiovascular risk assessment and management. Am. J. Cardiovasc. Drugs 7(4), 259-272 (2007).
    • (2007) Am. J. Cardiovasc. Drugs , vol.7 , Issue.4 , pp. 259-272
    • Wong, N.D.1
  • 5
    • 26244432388 scopus 로고    scopus 로고
    • Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    • Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005).
    • (2005) Lancet , vol.366 , Issue.9493 , pp. 1267-1278
    • Baigent, C.1    Keech, A.2    Kearney, P.M.3
  • 6
    • 33947378229 scopus 로고    scopus 로고
    • Risk of cardiovascular events in patients at optimal values for combined lipid parameters
    • Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ: Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr. Med. Res. Opin. 23(3), 553-563 (2007).
    • (2007) Curr. Med. Res. Opin. , vol.23 , Issue.3 , pp. 553-563
    • Stanek, E.J.1    Sarawate, C.2    Willey, V.J.3    Charland, S.L.4    Cziraky, M.J.5
  • 7
    • 56349154187 scopus 로고    scopus 로고
    • The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia
    • Fruchart JC, Sacks F, Hermans MP et al.: The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol. 102(10 Suppl.), 1K-34K (2008).
    • (2008) Am. J. Cardiol. , vol.102 , Issue.10 SUPPL.
    • Fruchart, J.C.1    Sacks, F.2    Hermans, M.P.3
  • 8
    • 15444375616 scopus 로고    scopus 로고
    • Rationale for combination therapy with statin drugs in the treatment of dyslipidemia
    • Ansell BJ: Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Curr. Atheroscler. Rep. 7(1), 29-33 (2005).
    • (2005) Curr. Atheroscler. Rep. , vol.7 , Issue.1 , pp. 29-33
    • Ansell, B.J.1
  • 9
    • 73849086222 scopus 로고    scopus 로고
    • Combination therapy of statins and fibrates in the management of cardiovascular risk
    • Fievet C, Staels B: Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr. Opin. Lipidol. 20(6), 505-511 (2009).
    • (2009) Curr. Opin. Lipidol. , vol.20 , Issue.6 , pp. 505-511
    • Fievet, C.1    Staels, B.2
  • 10
    • 3142729178 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    • Grundy SM, Cleeman JI, Merz CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2), 227-239 (2004).
    • (2004) Circulation , vol.110 , Issue.2 , pp. 227-239
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.3
  • 11
    • 23744475368 scopus 로고    scopus 로고
    • Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: Benefits versus risks
    • McKenney JM: Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am. J. Cardiol. 96(4A), 60E-66E (2005).
    • (2005) Am. J. Cardiol. , vol.96 , Issue.4 A
    • McKenney, J.M.1
  • 12
    • 15944410609 scopus 로고    scopus 로고
    • Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    • LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14), 1425-1435 (2005).
    • (2005) N. Engl. J. Med. , vol.352 , Issue.14 , pp. 1425-1435
    • Larosa, J.C.1    Grundy, S.M.2    Waters, D.D.3
  • 14
    • 0038236574 scopus 로고    scopus 로고
    • Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: A critical review of potential benefits and drawbacks
    • Farnier M: Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. Am. J. Cardiovasc. Drugs 3(3), 169-178 (2003).
    • (2003) Am. J. Cardiovasc. Drugs , vol.3 , Issue.3 , pp. 169-178
    • Farnier, M.1
  • 15
    • 13144290929 scopus 로고    scopus 로고
    • Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: Fibrates, statins or both?
    • Tenenbaum A, Fisman EZ: Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? Cardiovasc. Diabetol. 3, 10 (2004).
    • (2004) Cardiovasc. Diabetol. , vol.3 , pp. 10
    • Tenenbaum, A.1    Fisman, E.Z.2
  • 16
    • 33749536035 scopus 로고    scopus 로고
    • Atherogenic dyslipidemia in metabolic syndrome and Type 2 diabetes: Therapeutic options beyond statins
    • Tenenbaum A, Fisman EZ, Motro M, Adler Y: Atherogenic dyslipidemia in metabolic syndrome and Type 2 diabetes: therapeutic options beyond statins. Cardiovasc. Diabetol. 5, 20 (2006).
    • (2006) Cardiovasc. Diabetol. , vol.5 , pp. 20
    • Tenenbaum, A.1    Fisman, E.Z.2    Motro, M.3    Adler, Y.4
  • 17
    • 43749083758 scopus 로고    scopus 로고
    • Optimal management of combined dyslipidemia: What have we behind statins monotherapy?
    • Tenenbaum A, Fisman EZ, Motro M, Adler Y: Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv. Cardiol. 45, 127-153 (2008).
    • (2008) Adv. Cardiol. , vol.45 , pp. 127-153
    • Tenenbaum, A.1    Fisman, E.Z.2    Motro, M.3    Adler, Y.4
  • 18
    • 48549093490 scopus 로고    scopus 로고
    • National Lipid Association Taskforce on Non-HDL Cholesterol: The importance of non-HDL cholesterol reporting in lipid management
    • Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA; National Lipid Association Taskforce on Non-HDL Cholesterol: The importance of non-HDL cholesterol reporting in lipid management. J. Clin. Lipid. 2, 267-273 (2008).
    • (2008) J. Clin. Lipid. , vol.2 , pp. 267-273
    • Blaha, M.J.1    Blumenthal, R.S.2    Brinton, E.A.3    Jacobson, T.A.4
  • 19
    • 58249086417 scopus 로고    scopus 로고
    • Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk
    • Robinson JG, Wang S, Smith BJ, Jacobson TA: Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J. Am. Coll. Cardiol. 53(4), 316-322 (2009).
    • (2009) J. Am. Coll. Cardiol. , vol.53 , Issue.4 , pp. 316-322
    • Robinson, J.G.1    Wang, S.2    Smith, B.J.3    Jacobson, T.A.4
  • 20
    • 0036636769 scopus 로고    scopus 로고
    • Atorvastatin and micronized fenofibrate alone and in combination in Type 2 diabetes with combined hyperlipidemia
    • Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG: Atorvastatin and micronized fenofibrate alone and in combination in Type 2 diabetes with combined hyperlipidemia. Diabetes Care 25(7), 1198-1202 (2002).
    • (2002) Diabetes Care , vol.25 , Issue.7 , pp. 1198-1202
    • Athyros, V.G.1    Papageorgiou, A.A.2    Athyrou, V.V.3    Demitriadis, D.S.4    Kontopoulos, A.G.5
  • 21
    • 59049086841 scopus 로고    scopus 로고
    • Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia
    • Goldberg AC, Bays HE, Ballantyne CM et al.: Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am. J. Cardiol. 103(4), 515-522 (2009).
    • (2009) Am. J. Cardiol. , vol.103 , Issue.4 , pp. 515-522
    • Goldberg, A.C.1    Bays, H.E.2    Ballantyne, C.M.3
  • 22
    • 13844272245 scopus 로고    scopus 로고
    • Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)
    • Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J: Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol. 95(4), 462-468 (2005).
    • (2005) Am. J. Cardiol. , vol.95 , Issue.4 , pp. 462-468
    • Grundy, S.M.1    Vega, G.L.2    Yuan, Z.3    Battisti, W.P.4    Brady, W.E.5    Palmisano, J.6
  • 23
    • 57149105884 scopus 로고    scopus 로고
    • Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A Phase 3, randomized, controlled study
    • Mohiuddin SM, Pepine CJ, Kelly MT et al.: Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a Phase 3, randomized, controlled study. Am. Heart J. 157(1), 195-203 (2009).
    • (2009) Am. Heart J. , vol.157 , Issue.1 , pp. 195-203
    • Mohiuddin, S.M.1    Pepine, C.J.2    Kelly, M.T.3
  • 24
    • 0037446467 scopus 로고    scopus 로고
    • Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome
    • Vega GL, Ma PT, Cater NB et al.: Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am. J. Cardiol. 91(8), 956-960 (2003).
    • (2003) Am. J. Cardiol. , vol.91 , Issue.8 , pp. 956-960
    • Vega, G.L.1    Ma, P.T.2    Cater, N.B.3
  • 26
    • 0035924635 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism
    • Fruchart JC: Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism. Am. J. Cardiol. 88(12A), 24N-29N (2001).
    • (2001) Am. J. Cardiol. , vol.88 , Issue.12 A
    • Fruchart, J.C.1
  • 27
    • 26844431513 scopus 로고    scopus 로고
    • Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: The bezafibrate lessons
    • Tenenbaum A, Motro M, Fisman EZ: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc. Diabetol. 4, 14 (2005).
    • (2005) Cardiovasc. Diabetol. , vol.4 , pp. 14
    • Tenenbaum, A.1    Motro, M.2    Fisman, E.Z.3
  • 28
    • 77952422358 scopus 로고    scopus 로고
    • The effect of PPAR - A agonism on apolipoprotein metabolism in humans
    • Shah A, Rader DJ, Millar JS: The effect of PPAR-a agonism on apolipoprotein metabolism in humans. Atherosclerosis 210(1), 35-40 (2009).
    • (2009) Atherosclerosis , vol.210 , Issue.1 , pp. 35-40
    • Shah, A.1    Rader, D.J.2    Millar, J.S.3
  • 29
    • 70349342714 scopus 로고    scopus 로고
    • Effect of fibrates on lipid profiles and cardiovascular outcomes: A systematic review
    • 962
    • Abourbih S, Filion KB, Joseph L et al.: Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am. J. Med. 122(10), 962 E1-E8 (2009).
    • (2009) Am. J. Med. , vol.122 , Issue.10
    • Abourbih, S.1    Filion, K.B.2    Joseph, L.3
  • 31
    • 18744384338 scopus 로고    scopus 로고
    • Efficacy and safety of rosuvastatin in treatment of dyslipidemia
    • McKenney JM: Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am. J. Health. Syst. Pharm. 62(10), 1033-1047 (2005).
    • (2005) Am. J. Health. Syst. Pharm. , vol.62 , Issue.10 , pp. 1033-1047
    • McKenney, J.M.1
  • 32
    • 0038645309 scopus 로고    scopus 로고
    • Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial)
    • Jones PH, Davidson MH, Stein EA et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am. J. Cardiol. 92(2), 152-160 (2003).
    • (2003) Am. J. Cardiol. , vol.92 , Issue.2 , pp. 152-160
    • Jones, P.H.1    Davidson, M.H.2    Stein, E.A.3
  • 33
    • 56749106312 scopus 로고    scopus 로고
    • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • Ridker PM, Danielson E, Fonseca FA et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195-2207 (2008).
    • (2008) N. Engl. J. Med. , vol.359 , Issue.21 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.3
  • 34
    • 52949107622 scopus 로고    scopus 로고
    • Treatment of hyperlipidaemia with fenofibrate and related fibrates
    • Filippatos T, Milionis HJ: Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin. Investig. Drugs 17(10), 1599-1614 (2008).
    • (2008) Expert Opin. Investig. Drugs , vol.17 , Issue.10 , pp. 1599-1614
    • Filippatos, T.1    Milionis, H.J.2
  • 35
    • 0031909536 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of fibric acid derivatives (fibrates)
    • Miller DB, Spence JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet. 34(2), 155-162 (1998).
    • (1998) Clin. Pharmacokinet. , vol.34 , Issue.2 , pp. 155-162
    • Miller, D.B.1    Spence, J.D.2
  • 36
    • 58149181570 scopus 로고    scopus 로고
    • ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans
    • Zhu T, Awni WM, Hosmane B et al.: ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J. Clin. Pharmacol. 49(1), 63-71 (2009).
    • (2009) J. Clin. Pharmacol. , vol.49 , Issue.1 , pp. 63-71
    • Zhu, T.1    Awni, W.M.2    Hosmane, B.3
  • 37
    • 33750595221 scopus 로고    scopus 로고
    • An assessment of statin safety
    • McKenney JM: An assessment of statin safety. Am. J. Manag. Care 12(11 Suppl.), S310-S317 (2006).
    • (2006) Am. J. Manag. Care , vol.12 , Issue.11 SUPPL.
    • McKenney, J.M.1
  • 38
    • 67249111853 scopus 로고    scopus 로고
    • Narrative review: Statin-related myopathy
    • Joy TR, Hegele RA: Narrative review: statin-related myopathy. Ann. Intern. Med. 150(12), 858-868 (2009).
    • (2009) Ann. Intern. Med. , vol.150 , Issue.12 , pp. 858-868
    • Joy, T.R.1    Hegele, R.A.2
  • 39
    • 77149180421 scopus 로고    scopus 로고
    • Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia
    • Kostapanos MS, Milionis HJ, Elisaf MS: Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am. J. Cardiovasc. Drugs 10(1), 11-28 (2010).
    • (2010) Am. J. Cardiovasc. Drugs , vol.10 , Issue.1 , pp. 11-28
    • Kostapanos, M.S.1    Milionis, H.J.2    Elisaf, M.S.3
  • 40
    • 34248223741 scopus 로고    scopus 로고
    • Safety of rosuvastatin: Update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program
    • Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J: Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 107(4), 433-443 (2007).
    • (2007) Cardiology , vol.107 , Issue.4 , pp. 433-443
    • Shepherd, J.1    Vidt, D.G.2    Miller, E.3    Harris, S.4    Blasetto, J.5
  • 41
    • 0035337643 scopus 로고    scopus 로고
    • Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate
    • Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ: Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69(5), 340-345 (2001).
    • (2001) Clin. Pharmacol. Ther. , vol.69 , Issue.5 , pp. 340-345
    • Kyrklund, C.1    Backman, J.T.2    Kivisto, K.T.3    Neuvonen, M.4    Laitila, J.5    Neuvonen, P.J.6
  • 42
    • 11144354934 scopus 로고    scopus 로고
    • The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
    • Schneck DW, Birmingham BK, Zalikowski JA et al.: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75(5), 455-463 (2004).
    • (2004) Clin. Pharmacol. Ther. , vol.75 , Issue.5 , pp. 455-463
    • Schneck, D.W.1    Birmingham, B.K.2    Zalikowski, J.A.3
  • 43
    • 0037534010 scopus 로고    scopus 로고
    • Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
    • DOI 10.1016/S0009-9236(03)00052-3
    • Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ: Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther. 73(6), 538-544 (2003). (Pubitemid 37249124)
    • (2003) Clinical Pharmacology and Therapeutics , vol.73 , Issue.6 , pp. 538-544
    • Kyrklund, C.1    Backman, J.T.2    Neuvonen, M.3    Neuvonen, P.J.4
  • 44
    • 70349334010 scopus 로고    scopus 로고
    • Myopathy with statin-fibrate combination therapy: Clinical considerations
    • Jacobson TA: Myopathy with statin-fibrate combination therapy: clinical considerations. Nat. Rev. Endocrinol. 5(9), 507-518 (2009).
    • (2009) Nat. Rev. Endocrinol. , vol.5 , Issue.9 , pp. 507-518
    • Jacobson, T.A.1
  • 46
    • 30344436628 scopus 로고    scopus 로고
    • Statin/fibrate combination in patients with metabolic syndrome or diabetes: Evaluating the risks of pharmacokinetic drug interactions
    • Davidson MH: Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin. Drug Saf. 5(1), 145-156 (2006).
    • (2006) Expert Opin. Drug Saf. , vol.5 , Issue.1 , pp. 145-156
    • Davidson, M.H.1
  • 47
    • 11144239674 scopus 로고    scopus 로고
    • Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
    • Jones PH, Davidson MH: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. 95(1), 120-122 (2005).
    • (2005) Am. J. Cardiol. , vol.95 , Issue.1 , pp. 120-122
    • Jones, P.H.1    Davidson, M.H.2
  • 48
    • 0037292311 scopus 로고    scopus 로고
    • An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers
    • Martin PD, Dane AL, Schneck DW, Warwick MJ: An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin. Ther. 25(2), 459-471 (2003).
    • (2003) Clin. Ther. , vol.25 , Issue.2 , pp. 459-471
    • Martin, P.D.1    Dane, A.L.2    Schneck, D.W.3    Warwick, M.J.4
  • 49
    • 67349119255 scopus 로고    scopus 로고
    • Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A Phase 3 study
    • Jones PH, Davidson MH, Kashyap ML et al.: Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a Phase 3 study. Atherosclerosis 204(1), 208-215 (2009).
    • (2009) Atherosclerosis , vol.204 , Issue.1 , pp. 208-215
    • Jones, P.H.1    Davidson, M.H.2    Kashyap, M.L.3
  • 50
    • 77649209632 scopus 로고    scopus 로고
    • A Phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT-335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemia
    • Roth EM, Rosenson RS, Carlson DM et al.: A Phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT-335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemia. J. Am. Coll. Cardiol. 53(Suppl. A), A208 (2009).
    • (2009) J. Am. Coll. Cardiol. , vol.53 , Issue.SUPPL. A
    • Roth, E.M.1    Rosenson, R.S.2    Carlson, D.M.3
  • 51
    • 1842559795 scopus 로고    scopus 로고
    • Rosuvastatin and fenofibrate alone and in combination in Type 2 diabetes patients with combined hyperlipidaemia
    • Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K: Rosuvastatin and fenofibrate alone and in combination in Type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res. Clin. Pract. 64(2), 137-151 (2004).
    • (2004) Diabetes Res. Clin. Pract. , vol.64 , Issue.2 , pp. 137-151
    • Durrington, P.N.1    Tuomilehto, J.2    Hamann, A.3    Kallend, D.4    Smith, K.5
  • 52
    • 0036040929 scopus 로고    scopus 로고
    • Effects of fibrates on serum metabolic parameters
    • Elisaf M: Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18(5), 269-276 (2002).
    • (2002) Curr. Med. Res. Opin. , vol.18 , Issue.5 , pp. 269-276
    • Elisaf, M.1
  • 53
    • 0141794167 scopus 로고    scopus 로고
    • Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)
    • Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L: Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am. J. Cardiol. 92(7), 794-797 (2003).
    • (2003) Am. J. Cardiol. , vol.92 , Issue.7 , pp. 794-797
    • Farnier, M.1    Salko, T.2    Isaacsohn, J.L.3    Troendle, A.J.4    Dejager, S.5    Gonasun, L.6
  • 54
    • 5144227019 scopus 로고    scopus 로고
    • The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
    • Fazio S, Linton MF: The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr. Atheroscler. Rep. 6(2), 148-157 (2004).
    • (2004) Curr. Atheroscler. Rep. , vol.6 , Issue.2 , pp. 148-157
    • Fazio, S.1    Linton, M.F.2
  • 55
    • 34547687824 scopus 로고    scopus 로고
    • Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome
    • Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW: Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30(8), 1945-1951 (2007).
    • (2007) Diabetes Care , vol.30 , Issue.8 , pp. 1945-1951
    • Rosenson, R.S.1    Wolff, D.A.2    Huskin, A.L.3    Helenowski, I.B.4    Rademaker, A.W.5
  • 56
    • 0036238785 scopus 로고    scopus 로고
    • A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients
    • Lemieux I, Laperriere L, Dzavik V, Tremblay G, Bourgeois J, Despres JP: A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 162(2), 363-371 (2002).
    • (2002) Atherosclerosis , vol.162 , Issue.2 , pp. 363-371
    • Lemieux, I.1    Laperriere, L.2    Dzavik, V.3    Tremblay, G.4    Bourgeois, J.5    Despres, J.P.6
  • 57
    • 57349155535 scopus 로고    scopus 로고
    • Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia
    • Bays HE, Jones PH, Mohiuddin SM et al.: Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J. Clin. Lipid. 2, 426-435 (2008).
    • (2008) J. Clin. Lipid. , vol.2 , pp. 426-435
    • Bays, H.E.1    Jones, P.H.2    Mohiuddin, S.M.3
  • 58
    • 72049124300 scopus 로고    scopus 로고
    • Year two assessment of fenofibric acid and moderate-dose statin combination
    • Kipnes MS, Roth EM, Rhyne JM et al.: Year two assessment of fenofibric acid and moderate-dose statin combination. Clin. Drug Invest. 30(1), 51-61 (2010).
    • (2010) Clin. Drug Invest. , vol.30 , Issue.1 , pp. 51-61
    • Kipnes, M.S.1    Roth, E.M.2    Rhyne, J.M.3
  • 59
    • 28044452217 scopus 로고    scopus 로고
    • Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
    • Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849-1861 (2005).
    • (2005) Lancet , vol.366 , Issue.9500 , pp. 1849-1861
    • Keech, A.1    Simes, R.J.2    Barter, P.3
  • 60
    • 64749095070 scopus 로고    scopus 로고
    • Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with Type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    • Scott R, O'Brien R, Fulcher G et al.: Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with Type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32(3), 493-498 (2009).
    • (2009) Diabetes Care , vol.32 , Issue.3 , pp. 493-498
    • Scott, R.1    O'brien, R.2    Fulcher, G.3
  • 61
    • 77953264127 scopus 로고    scopus 로고
    • Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia - A randomized study
    • Roth EM, McKenney JM, Kelly MT et al.: Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia - a randomized study. Am. J. Cardiovasc. Drugs, 10(3), 175-186 (2010).
    • (2010) Am. J. Cardiovasc. Drugs , vol.10 , Issue.3 , pp. 175-186
    • Roth, E.M.1    McKenney, J.M.2    Kelly, M.T.3
  • 62
    • 78149438296 scopus 로고    scopus 로고
    • A Phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT-335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemia
    • Presented at, Orlando, FL, USA, 29-31 March
    • Roth EM, Rosenson RS, Carlson DM et al.: A Phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT-335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemia. Presented at: 58th Annual Scientific Session of the American College of Cardiology. Orlando, FL, USA, 29-31 March 2009.
    • (2009) 58th Annual Scientific Session of the American College of Cardiology
    • Roth, E.M.1    Rosenson, R.S.2    Carlson, D.M.3
  • 63
    • 77951704587 scopus 로고    scopus 로고
    • Effects of combination lipid therapy in Type 2 diabetes mellitus
    • Ginsberg HN, Elam MB, Lovato LC et al.: Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1563-1574 (2010).
    • (2010) N. Engl. J. Med. , vol.362 , Issue.17 , pp. 1563-1574
    • Ginsberg, H.N.1    Elam, M.B.2    Lovato, L.C.3
  • 64
    • 19344375593 scopus 로고    scopus 로고
    • Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome
    • Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med. 165(10), 1154-1160 (2005).
    • (2005) Arch. Intern. Med. , vol.165 , Issue.10 , pp. 1154-1160
    • Tenenbaum, A.1    Motro, M.2    Fisman, E.Z.3    Tanne, D.4    Boyko, V.5    Behar, S.6
  • 65
    • 0033527030 scopus 로고    scopus 로고
    • Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
    • Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
    • Rubins HB, Robins SJ, Collins D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341(6), 410-418 (1999).
    • (1999) N. Engl. J. Med. , vol.341 , Issue.6 , pp. 410-418
    • Rubins, H.B.1    Robins, S.J.2    Collins, D.3
  • 66
    • 66349088277 scopus 로고    scopus 로고
    • Relationships of HDL cholesterol, apoAI, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate
    • Taskinen MR, Sullivan DR, Ehnholm C et al.: Relationships of HDL cholesterol, apoAI, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate. Arterioscler. Thromb. Vasc. Biol. 29(6), 950-955 (2009).
    • (2009) Arterioscler. Thromb. Vasc. Biol. , vol.29 , Issue.6 , pp. 950-955
    • Taskinen, M.R.1    Sullivan, D.R.2    Ehnholm, C.3
  • 67
    • 77952708442 scopus 로고    scopus 로고
    • Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis
    • Jun M, Foote C, Lv J et al.: Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375(9729), 1875-1884 (2010).
    • (2010) Lancet , vol.375 , Issue.9729 , pp. 1875-1884
    • Jun, M.1    Foote, C.2    Lv, J.3
  • 68
    • 11344279659 scopus 로고    scopus 로고
    • C-reactive protein levels and outcomes after statin therapy
    • Ridker PM, Cannon CP, Morrow D et al.: C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352(1), 20-28 (2005).
    • (2005) N. Engl. J. Med. , vol.352 , Issue.1 , pp. 20-28
    • Ridker, P.M.1    Cannon, C.P.2    Morrow, D.3
  • 69
    • 78149454768 scopus 로고    scopus 로고
    • Kowa Pharmaceuticals America Inc., AL, USA
    • LIVALO®, prescribing information. Kowa Pharmaceuticals America Inc., AL, USA (2009).
    • (2009) LIVALO®, Prescribing Information
  • 70
    • 0141988934 scopus 로고    scopus 로고
    • Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor
    • Kajinami K, Takekoshi N, Saito Y: Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev. 21(3), 199-215 (2003).
    • (2003) Cardiovasc. Drug Rev. , vol.21 , Issue.3 , pp. 199-215
    • Kajinami, K.1    Takekoshi, N.2    Saito, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.